212 related articles for article (PubMed ID: 11350411)
1. Side-effects of oral or intravesical oxybutynin chloride in children with spina bifida.
Ferrara P; D'Aleo CM; Tarquini E; Salvatore S; Salvaggio E
BJU Int; 2001 May; 87(7):674-8. PubMed ID: 11350411
[TBL] [Abstract][Full Text] [Related]
2. Complications of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population.
Palmer LS; Zebold K; Firlit CF; Kaplan WE
J Urol; 1997 Feb; 157(2):638-40. PubMed ID: 8996387
[TBL] [Abstract][Full Text] [Related]
3. [Intravesical oxybutynin in children with meningomyelocele. Efficient treatment with few side-effects].
Von Zweigbergk M; Nordin B; Jonsson S
Lakartidningen; 1996 Oct; 93(41):3573-6. PubMed ID: 8965514
[No Abstract] [Full Text] [Related]
4. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters.
Humblet M; Verpoorten C; Christiaens MH; Hirche H; Jansen K; Buyse G; van Gool JD
Neurourol Urodyn; 2015 Apr; 34(4):336-42. PubMed ID: 24436114
[TBL] [Abstract][Full Text] [Related]
5. Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients.
Haferkamp A; Staehler G; Gerner HJ; Dörsam J
Spinal Cord; 2000 Apr; 38(4):250-4. PubMed ID: 10822396
[TBL] [Abstract][Full Text] [Related]
6. Follow-up of long-time treatment with intravesical oxybutynin for neurogenic bladder in children.
Amark P; Bussman G; Eksborg S
Eur Urol; 1998 Aug; 34(2):148-53. PubMed ID: 9693251
[TBL] [Abstract][Full Text] [Related]
7. Expanded followup of intravesical oxybutynin chloride use in children with neurogenic bladder.
Kaplinsky R; Greenfield S; Wan J; Fera M
J Urol; 1996 Aug; 156(2 Pt 2):753-6. PubMed ID: 8683776
[TBL] [Abstract][Full Text] [Related]
8. Can Oral Fesoterodine Be an Alternative for Intravesical Oxybutynin Instillations in Children with Neuropathic Bladder Dysfunction?
van den Heijkant M; De Coster K; Jansen K; Bogaert G
Urol Int; 2019; 103(2):202-210. PubMed ID: 31117096
[TBL] [Abstract][Full Text] [Related]
9. Treatment of neurogenic bladder dysfunction in infants and children with neurospinal dysraphism with clean intermittent (self)catheterisation and optimized intravesical oxybutynin hydrochloride therapy.
Buyse G; Verpoorten C; Vereecken R; Casaer P
Eur J Pediatr Surg; 1995 Dec; 5 Suppl 1():31-4. PubMed ID: 8770576
[TBL] [Abstract][Full Text] [Related]
10. Combined intravesical and oral oxybutynin chloride in adult patients with spinal cord injury.
Pannek J; Sommerfeld HJ; Bötel U; Senge T
Urology; 2000 Mar; 55(3):358-62. PubMed ID: 10699610
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity.
Lehtoranta K; Tainio H; Lukkari-Lax E; Hakonen T; Tammela TL
Scand J Urol Nephrol; 2002 Feb; 36(1):18-24. PubMed ID: 12002352
[TBL] [Abstract][Full Text] [Related]
12. Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism.
Buyse G; Waldeck K; Verpoorten C; Björk H; Casaer P; Andersson KE
J Urol; 1998 Sep; 160(3 Pt 1):892-6. PubMed ID: 9720583
[TBL] [Abstract][Full Text] [Related]
13. Detrusor overactivity in spina bifida: how long does it need to be treated?
Ab E; Dik P; Klijn AJ; van Gool JD; de Jong TP
Neurourol Urodyn; 2004; 23(7):685-8. PubMed ID: 15382196
[TBL] [Abstract][Full Text] [Related]
14. Intravesical application of a stable oxybutynin solution improves therapeutic compliance and acceptance in children with neurogenic bladder dysfunction.
Buyse G; Verpoorten C; Vereecken R; Casaer P
J Urol; 1998 Sep; 160(3 Pt 2):1084-7; discussion 1092. PubMed ID: 9719281
[TBL] [Abstract][Full Text] [Related]
15. Intravesical therapy for the treatment of neurogenic bladder in children.
Holland AJ; King PA; Chauvel PJ; O'Neill MK; McKnight DL; Barker AP
Aust N Z J Surg; 1997 Oct; 67(10):731-3. PubMed ID: 9322726
[TBL] [Abstract][Full Text] [Related]
16. Intravesical instillation of oxybutynin hydrochloride therapy for patients with a neuropathic bladder.
Mizunaga M; Miyata M; Kaneko S; Yachiku S; Chiba K
Paraplegia; 1994 Jan; 32(1):25-9. PubMed ID: 8015832
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and effects of intravesical oxybutynin on the paediatric neurogenic bladder.
Amark P; Eksborg S; Juneskans O; Bussman G; Palm C
Br J Urol; 1998 Dec; 82(6):859-64. PubMed ID: 9883225
[TBL] [Abstract][Full Text] [Related]
18. Long-term intravesical oxybutynin chloride therapy in children with myelodysplasia.
Painter KA; Vates TS; Bukowski TP; Fleming P; Freedman AL; Smith CA; Gonzalez R; Perlmutter AD
J Urol; 1996 Oct; 156(4):1459-62. PubMed ID: 8808907
[TBL] [Abstract][Full Text] [Related]
19. Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience.
Saito M; Watanabe T; Tabuchi F; Otsubo K; Satoh K; Miyagawa I
Int J Urol; 2004 Aug; 11(8):592-6. PubMed ID: 15285747
[TBL] [Abstract][Full Text] [Related]
20. Intravesical oxybutynin chloride and clean intermittent catheterisation in patients with neurogenic vesical dysfunction and decreased bladder capacity.
Prasad KV; Vaidyanathan S
Br J Urol; 1993 Nov; 72(5 Pt 2):719-22. PubMed ID: 8281402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
